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Abstract
Background: The GOLD classification of COPD severity introduces a stage 0 (at risk) comprising
individuals with productive cough and normal lung function. The aims of this study were to investigate total
mortality risks in GOLD stages 0–4 with special focus on stage 0, and furthermore to assess the influence
of symptoms of chronic bronchitis on mortality risks in GOLD stages 1–4.
Method: Between 1974 and 1992, a total of 22 044 middle-aged individuals participated in a health
screening, which included a spirometry as well as recording of respiratory symptoms and smoking habits.
Individuals with comorbidity at baseline (diabetes, stroke, cancer, angina pectoris, or heart infarction) were
excluded from the analyses. Hazard ratios (HR 95% CI) of total mortality were analyzed in GOLD stages
0–4 with individuals with normal lung function and without symptoms of chronic bronchitis as a reference
group. HR:s in smoking individuals with symptoms of chronic bronchitis within the stages 1–4 were
calculated with individuals with the same GOLD stage but without symptoms of chronic bronchitis as
reference.
Results: The number of deaths was 3674 for men and 832 for women based on 352 324 and 150 050
person-years respectively. The proportion of smokers among men was 50% and among women 40%. Self
reported comorbidity was present in 4.6% of the men and 6.6% of the women. Among smoking men, Stage
0 was associated with an increased mortality risk, HR; 1.65 (1.32–2.08), of similar magnitude as in stage 2,
HR; 1.41 (1.31–1.70). The hazard ratio in stage 0 was significantly higher than in stage 1 HR; 1.13 (0.98–
1.29). Among male smokers with stage 1; HR: 2.04 (1.34–3.11), and among female smokers with stage 2
disease; HR: 3.16 (1.38–7.23), increased HR:s were found in individuals with symptoms of chronic
bronchitis as compared to those without symptoms of chronic bronchitis.
Conclusion: Symptoms fulfilling the definition of chronic bronchitis were associated with an increased
mortality risk among male smokers with normal pulmonary function (stage 0) and also with an increased
risk of death among smoking individuals with mild to moderate COPD (stage 1 and 2).
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Chronic obstructive pulmonary disease (COPD) is a
major cause of increased morbidity and mortality [1]. The
Global Initiative for Chronic Obstructive Lung Diseases
(GOLD) guidelines were published in 2001 [2], and
revised in 2004 [3] with the aim of increasing awareness
of COPD and of decreasing morbidity and mortality from
the disease. The GOLD staging system for COPD intro-
duces a stage 0 (at risk), defined as the presence of chronic
respiratory symptoms such as productive cough in indi-
viduals with preserved normal pulmonary function. The
importance of the "at risk" stage, especially the effect of
productive cough on morbidity and mortality, is an issue
under debate [4]. To assess prognosis in patients with
established COPD, the BODE-index for prediction of
mortality (based on degree of airflow limitation, dyspnea,
6 min walking distance and body mass index) has been
developed [5]. The BODE index is probably less helpful in
the early stages of COPD when individuals may have no
symptoms or symptoms of chronic bronchitis only
("smoker's cough"), regarded by most individuals (and
physicians) as innocent symptoms. Contrary to this view,
some previous studies have shown an increased mortality
risk associated with symptoms of chronic bronchitis [6,7].
We hypothesized that chronic productive cough (symp-
toms of chronic bronchitis) could predict an increased
mortality risk. The aims of this study were firstly to inves-
tigate all-cause mortality risks in relation to GOLD stages
0–4 with special focus on stage 0. Secondly, the effect of
symptoms of chronic bronchitis on mortality risks in
GOLD stages 1–4 was also assessed.
Study Population and Methods
Study population
With a population of 250000 inhabitants, Malmö is Swe-
den's third largest city. The Malmö Preventive Program
(MPP), a preventive, case-finding programme for cardio-
vascular risk factors and alcohol abuse, was created in
1974 at the Department of Preventive Medicine of Malmö
University Hospital. The aim of this programme was to
screen large strata of the adult population, mostly middle-
aged men and women born in prespecified years, in order
to find high-risk individuals for preventive intervention
[8,9]. Between 1974 and 1992, a total of 22,444 men
(mean age 44 years range 27 – 61) and 10 902 women
(mean age 50 years, range 28 – 58) attended the pro-
gramme, with an overall attendance rate of 70% (range
64–78) [8]. The present study was based on prospectively
collected data including detailed data on smoking habits
obtained from 22,044 individuals with complete data on
smoking habits and lung function among the individuals
who took part in the MPP. The study population is
described in fig 1.
Screening procedure and intervention
All individuals who participated in the MPP took part in a
comprehensive health screening, which included a physi-
cal examination, spirometry and blood tests. Addition-
ally, lifestyle-related risk factors were assessed by means of
a self-administered questionnaire including questions on
smoking habits. Various interventions (lifestyle modifica-
tion, drug therapy) were offered to nearly 25% of the
screened individuals for shorter or longer periods [8,10].
Intervention against smoking was however only instituted
if another cardiovascular risk factor was present and con-
sisted of advice given by a nurse to stop smoking, some-
times supported by measurements of carboxyhemoglobin
(COHb) and feedback information to the individual with
a history of smoking [11].
Recording of tobacco smoking
All individuals completed a self-administered question-
naire regarding their tobacco consumption and inhala-
tion habits. Tobacco consumption was calculated by
equating one cigarette to 1 gram, one cheroot to 3 grams,
and one cigar to 5 grams of tobacco. Individuals were cat-
egorized according to their self-reported smoking habits.
Individuals who gave negative answers to all smoking-
related questions regarding current and previous smoking
habits were classified as never smokers. Individuals who
stated that they had stopped smoking and who gave neg-
ative answers to all other smoking-related questions were
classified as former smokers. Individuals who stated that
they were currently smoking were classified as smokers.
Those who gave contradictory answers were excluded. In
order to adjust for differences in the amount of tobacco
Flow chart of the study populationigure 1
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was used separating individuals who smoked 20 grams or
more tobacco per day from those who smoked less than
that amount.
Assessment of pulmonary function
Pulmonary function was assessed by a screening spirome-
try. A Spirotron® apparatus (Drägerwerk AG, Lűbeck, Ger-
many) was used with the individual in an upright
standing position without a nose clip. Specially trained
nurses performed the tests. Forced expiratory volume in
one second (FEV1) and forced vital capacity (FVC) were
recorded. One acceptable manoeuvre with respect to the
individual's cooperation and performance was required
[12]. FEV1 was analysed as percent of predicted (pred) val-
ues. Predicted values of FEV1 were obtained from an inter-
nally derived linear regression based on height and age in
a subgroup of 3467 male and 2961 female never-smokers.
Men: Pred. FEV1 (L): 4.422 × height (m) - 0.0381 × age
(year) - 2.483, SD 0.63
Women: Pred. FEV1 (L): 3.615 × height (m) - 0.0217 × age
- 2.134, SD 0.45
Assessment of respiratory symptoms
Respiratory symptoms were assessed by a self-adminis-
tered questionnaire. We used the classical definition of
chronic bronchitis. The questions regarding chronic pro-
ductive cough varied somewhat during the screening
period. In the period from screening start on the 1st Sep-
tember 1974 until the 1st March 1978 the following ques-
tion was used:
1."During any period of your life, have you had daily cough
lasting more than three months in more than two years?"
("Ever symptoms of symptoms of chronic bronchitis")
In the period from 2nd of March 1978 until the end of the
screening the following two questions were used :
2. "During the last two years have you had daily cough lasting
for more than 3 months", and
3. "During the last two years, have you had phlegm coming up
from your chest daily for more than three months? ("Recent
symptoms of chronic bronchitis")
Individuals who answered affirmatively to the first ques-
tion ("ever symptoms of chronic bronchitis" or both the
second and third question ("recent symptoms of chronic
bronchitis") were regarded as having symptoms of
chronic bronchitis corresponding to the definition of
GOLD stage 0.
Classification of pulmonary function
GOLD Stages 0–4 were defined as follows:
stage 0 FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% pred and symp-
toms of chronic bronchitis,
stage 1 (mild): FEV1/FVC < 0.70 and FEV1 ≥ 80% pred,
stage 2 (moderate): FEV1/FVC < 0.70 and FEV1 < 80% pred
and FEV1 ≥ 50% pred,
stage 3 (severe): FEV1/FVC < 0.70 and FEV1 < 50% pred
and FEV1 ≥ 30% pred,
stage 4 (very severe) : FEV1/FVC < 0.70 and FEV1 < 30%
pred,
Individuals without symptoms of chronic bronchitis and
with FEV/FVC ≥ 70 and FEV1 ≥ 80% predicted were classi-
fied as normal and used as a reference group throughout
the study except for the analyses of the effect of symptoms
of chronic bronchitis within stage 1–3 where individuals
with the same GOLD stage, but without symptoms of
chronic bronchitis were used as reference.
Assessment of comorbidity
Baseline comorbidity was assessed by a self-administered
questionnaire. Individuals who answered affirmatively to
any of the following four questions were regarded as hav-
ing significant comorbidity and were excluded from fur-
ther analyses.
1. "Have you previously had a stroke?"
2. "Have you a physician's diagnosis of angina pectoris?"
3. "Do you have diabetes?"
4. "Have you been hospitalised due to a heart infarction?"
5. "Have you previously or currently received a diagnosis of
cancer?"
Register follow-up analyses
All individuals were followed up in national registers for
total mortality until 31st December 2003. Cause-specific
mortality was assessed in male smokers of GOLD stage 0.
Notably, data on cause-specific mortality was only availa-
ble until 31st December 2002. The Swedish Board of
Health and Welfare provided data from national registers
on death certificates and cancer diagnoses. The overall
autopsy rate was 44% during the study period. The cases
were coded according to the International Classification
of Diseases ICD 8–10. Mortality for all causes of death,
cardiovascular disease (ICD 8–9: 401–414, 424, 426–Page 3 of 9
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I61–71), all cancer except for lung cancer (ICD 8–9: 140–
208; ICD 10: C00–C97), lung cancer (ICD 8–9: 162–165;
ICD10: C34, 38, 39, 45) and respiratory diseases (ICD 8–
9: 460–466, 480–487, 490–496, 500–503, 510–519;
ICD10: J00–99) were recorded. The vital status at Decem-
ber 31st 2003 was unknown in 412 individuals who had
left the country by that time. The accumulated person-
years until they left the country were used in the analyses.
Data analysis
The computer-based analysis programme, Statistical Pro-
gramme for Social Sciences (SPSS) version 10.0, was used
for all calculations. The Cox Proportional Hazards Regres-
sion Model [13] was used to calculate relative total mor-
tality rates in GOLD stages 0–4 with adjustments for age
only in never-smokers and former smokers. Cause specific
mortality was analysed only in smoking men of stage 0. In
smokers, adjustments were also made for tobacco con-
sumption (<20 grams/≥20 grams per day) and inhalation
habits (yes/no). The reference group in all analyses con-
sisted of individuals with normal pulmonary function
and without symptoms of chronic bronchitis. In order to
address possible differences in mortality risk between
"ever symptoms of chronic bronchitis and "recent symp-
toms of chronic bronchitis" we calculated the mortality
risk in GOLD stage 0 among smoking men using both
"ever symptoms of chronic bronchitis" and "recent symp-
toms of chronic bronchitis" for the definition of stage 0,
with the same adjustments and reference group as
described above. Among smokers, the influence of symp-
toms of chronic bronchitis was assessed comparing indi-
viduals with and without symptoms of chronic bronchitis
within the GOLD stages 1–4 after adjustment for age,
tobacco consumption and inhalation habits. All variables
were included in the analyses as categorical (yes/no)
except for age. All individuals with self-reported comor-
bidity at baseline were excluded from the analyses. All
analyses were performed separately for men and women.
A p-value of less than 0.05 was considered statistically
significant.
Results
Characteristics of the study population
The total number of deaths was 3674 among men and
832 in women based on 352 324 and 150 050 person-
years, respectively. Among men of GOLD stage 0, 217
individuals had "ever symptoms of chronic bronchitis"
and 101 individuals had "recent symptoms of chronic
bronchitis". The corresponding figures among women
were 33 and 142.
The proportion of current smokers was high at the time of
screening and slightly higher among men (50%) than
among women (40%). Former smokers were also more
common among men (27%) than among women (16%).
Among men, 24% of the individuals and among women,
40% stated that they had never smoked (never smokers).
Self-reported comorbidity was present in 4.6% of the men
and 6.6% of the women. The prevalence of COPD in the
study population was for men in GOLD stage 0–4: 2.2%,
9.9%, 6.9%, 1.0%, and 0.3%. The corresponding figures
among women were: 2.4%, 4.5%, 4.3%, 0.6%, and 0.2%
respectively, (Table 1).
Mortality risks in smokers
Among smoking men the hazard ratio (HR) increased
stepwise from stage 1 to stage 4 (p for trend < 0.0001).
Stage 1 showed a slightly increased HR (1.13) of border-
line significance and the HR increased further in stage 2
(1.41). In the later stages a pronounced increase in mor-
tality risk was seen. In stages 3 and 4 the risks increased
two- to tenfold, respectively, suggesting a possible thresh-
old with respect to an increased mortality risk at a FEV1
equal to or lower than 50% predicted. Among smoking
men, stage 0 was associated with significantly elevated
mortality risk, HR: 1.65 (1.32–2.08), of similar magni-
tude as in stage 2, HR: 1.41 (1.31–1.70), suggesting an
adverse influence of symptoms of chronic bronchitis on
mortality risks in these symptomatic smokers. The relative
risk in stage 0 was significantly higher than in stage 1; HR:
1.13 (0.98–1.29). No difference in mortality risk was seen
among smoking men of GOLD stage 0 when we used
Table 1: Characteristics of the study population*
Men Women
Number (n) 14 630 7414
Smoker 7221 (49.4) 2961 (39.9)
Exsmoker 3942 (26.9) 1169 (15.8)
Never-smoker 3467 (23.7) 2961 (39.9)
Age 46.4 (5.7) 47.5 (7.8)
Follow-up time 22.2 (5.7) 20.2 (4.7)
Person-years 352 324 150 050
Deaths 3674 (25.1) 832 (11.2)
Reference** 10215 (69.8) 5706 (77)
Not classif*** 1453 (9.9) 821 (11.0)
Gold 0 318 (2.2) 175 (2.4)
Gold 1 1443 (9.9) 336 (4.5)
Gold 2 1010 (6.9) 316 (4.3)
Gold 3 149 (1.0) 48 (0.6)
Gold 4 42 (0.3) 12 (0.2)
Comorbidity**** 676 (4.6) 489 (6.6)
* Data are given as numbers (%), but age and follow-up time are given 
as years (mean, standard deviation). ** Normal pulmonary function, 
without symptoms of chronic bronchitis
*** Not-classif: individuals not classified as normal or categorized 
according to the GOLD stages.
**** Self-reported previous/current stroke, angina pectoris diagnosed 
by a physician, diabetes, hospitalization due to a heart infarction or a 
diagnosis of cancer at baseline.Page 4 of 9
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HR: 1.62 (1.25–2.12 p-value: <0.0001) or "recent symp-
toms of chronic bronchitis" (101 individuals) HR: 1.74
(1.13–2.68 p-value: 0.012) to define stage 0. Among
smoking women, as for men, the HR:s in stage 1–4
increased stepwise (p for trend <0.0001). There was an
overlap in the confidence intervals in stages 1 and 2 with
no significant difference between the stages. As for men,
GOLD 3 and 4 conveyed an increase in mortality risk that
was significantly higher than in the other GOLD stages,
again suggesting a possible "threshold" at a FEV1 of 50%
predicted. The HR was slightly increased in stage 0, with a
similar magnitude as in smoking men but of borderline
significance, probably due to low statistical power or dif-
ferences in the influence of symptoms of chronic bronchi-
tis between genders, (Table 2).
Cause specific mortality among male smokers with GOLD 
stage 0
Among male smokers HR for cardiovascular mortality was
(16 deaths): 0.88 (0.53–1.44), p-value 0.60, mortality in
all cancer mortality except lung cancer: (22 deaths): 2.03
(1.31–3.15) p-value 0.001, mortality in lung cancer: (12
deaths) 2.22 (1.23–4.02), p-value: 0.008, other causes:
(24 deaths) 2.05 (1.45–2.88) p-value: <0.0001. Respira-
tory mortality was not analysed due to a lower number of
deaths, (only one death in respiratory diseases was
recorded in stage 0).
Mortality risks among former smokers and never smokers
Among male former smokers the numbers of deaths were
generally low except for stages 1 and 2, which showed no
increased mortality risk. Stage 0 was associated with an
increased risk, however the number of deaths was low and
the results should therefore be interpreted with caution.
This was also the case among male never smokers except
for stage 2 (32 deaths) that showed a significantly
increased HR of 1.73 (1.18–2.54), suggesting an effect of
low FEV1 also among never-smokers. Among former and
never-smoking women, the numbers of deaths were very
low in all GOLD stages and the results should therefore be
interpreted with caution, (Table 2).
The influence of symptoms of chronic bronchitis on 
mortality risks in stages 1 and 2
We compared subjects with and without self-reported
symptoms of chronic bronchitis at baseline and found
that the HR was significantly increased among male
smokers with symptoms of chronic bronchitis and mild
COPD (stage 1, with airflow limitation only) as compared
to those without symptoms of chronic bronchitis. Among
smoking women this was also the case among individuals
with moderate COPD (stage 2) suggesting an effect of
symptoms of chronic bronchitis on mortality risks in the
early stages of COPD, (Table 3).
Discussion
We investigated mortality risks in relation to the GOLD
classification of obstructive pulmonary disease in a large
Table 2: Mortality risks in GOLD stages 0–4 stratified for smoking status and gender*
Smoker*** Former smoker*** Never smoker***
Men N* Deaths RR** CI P-value N* Deaths RR CI p-value N* Deaths RR CI p-value
Ref 4430 1205 2993 517 2792 404
Gold 0 215 92 1.65 1.32–2.08 <0.0001 54 17 1.75 1.05–2.43 0.033 49 6 1.03 0.46–2.31 0.95
Gold 1 792 269 1.13 0.98–1.29 0.087 405 68 0.80 0.61–1.05 0.10 246 51 1.31 0.97–1.76 0.080
Gold 2 710 309 1.41 1.31–1.70 <0.0001 173 44 1.16 0.81–1.66 0.43 127 32 1.73 1.18–2.54 0.005
Gold 3 101 63 2.42 1.84–3.18 <0.0001 33 18 2.42 1.44–4.08 0.001 15 7 3.93 1.86–8.30 <0.0001
Gold 4 27 21 3.57 2.23–5.71 <0.0001 8 4 2.59 0.83–8.07 0.10 7 2 1.04 0.15–7.39 0.97
Women
Ref 2174 256 1 993 87 1 2539 168 1
Gold 0 108 17 1.64 0.98–2.73 0.060 25 1 0.53 0.07–3.79 0.53 42 7 3.12 1.46–6.67 0.003
Gold 1 184 39 1.75 1.22–2.51 0.002 46 2 0.23 0.03–1.65 0.14 106 8 0.83 0.37–1.87 0.64
Gold 2 234 52 1.75 1.27–2.42 0.001 32 5 1.48 0.59–3.67 0.40 50 7 2.11 0.99–4.52 0.054
Gold 3 36 19 5.11 3.09–8.45 <0.0001 5 1 NA 7 2 3.91 0.96–15.8 0.056
Gold 4 9 6 10.26 4.53–23.25 <0.0001 0 0 NA 3 1 18.10 2.53–129.6 0.0004
* Individuals with self-reported baseline comorbidity (current/previous cancer, stroke, angina pectoris, heart infarction or diabetes) were excluded. 
GOLD stage 4 were not analysed due to low number of cases. The reference group consists of individuals without chronic bronchitis and with 
normal pulmonary function.
** HR denotes hazard ratio with CI 95% confidence interval.
*** In smokers adjustments were made for age, inhalation habits (yes/no) and tobacco consumption (>=20 g/<20 g tobacco). In former and never-
smokers adjustments were made for age only.Page 5 of 9
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women. The main findings were firstly that among smok-
ers, symptoms of chronic bronchitis were associated with
increased total mortality risk among individuals with nor-
mal pulmonary function (corresponding to GOLD stage
0) and among those with mild to moderate COPD
(GOLD stage 1 and 2). Secondly, among male smokers of
stage 0, cause-specific mortality showed increased HR for
all cancer (except lung cancer), lung cancer and other dis-
eases. Thirdly, the total mortality hazard ratio in stages 1–
4 increased stepwise with a pronounced increase in risk at
a level of FEV1 below 50% predicted, suggesting a thresh-
old effect in mortality risk at this level. Individuals with
comorbidity of cardiovascular disease, diabetes and can-
cer at baseline were excluded and we have adjusted for age
and smoking habits as completely as possible including
tobacco consumption and inhalation habits.
Comparison with other studies
Prevalence of stage 0
The prevalence of individuals with stage 0 in our study
was 2.2% in men and 2.4% in women. In the Copenha-
gen City Heart study the prevalence was slightly higher;
criteria for GOLD Stage 0 were met in 5.8% of the total
adult population and in 7.2% of smokers [4]. In the
National Health and Nutrition Examination Study
(NHANES) study [14] the prevalence of respiratory symp-
toms among individuals with normal pulmonary func-
tion was substantially higher (approximately 13%). This
is probably mostly dependent on different selection crite-
ria due to variation in the definition of stage 0. Vestbo and
coworkers limited the selection of individuals to those
with symptoms of chronic bronchitis but included all
individuals without airflow limitation irrespective of the
level of FEV1. On the other hand the NHANES study had
higher prevalence rates probably due to a broader defini-
tion of the respiratory symptoms [14]. In our study a spe-
cific definition of symptoms of chronic bronchitis was
used and we only selected individuals with normal pul-
monary function, both with respect to FEV1 and the FEV1/
FVC ratio. Consequently the prevalence of stage 0 was
lower in our study than in the NHANES [14] and the
Copenhagen City Heart study [4].
Mortality risks associated with symptoms of chronic bronchitis
Among male smokers of our study, the HR of total mor-
tality in GOLD stage 0 was strongly significant irrespective
of whether we used "ever" or "recent" symptoms of
chronic bronchitis" to define stage 0. The HR:s were of a
similar magnitude as for stage 2. Among men with GOLD
stage 1 in men and among women with stage 2 in women,
increased HR:s were noticed in smokers who reported
symptoms of chronic bronchitis, implying that respiratory
symptoms might be important for an adverse prognosis.
However, in GOLD stage 3 we were not able to show an
additive risk associated with symptoms of chronic bron-
chitis possibly due to low statistical power.
Similar results have previously been demonstrated in
some studies. In the Copenhagen City Heart study,
chronic mucus hypersecretion was associated with an
increased risk of all cause mortality statistically significant
in men only (relative risk: 1.3 in men and 1.1 in women)
[7]. There was no interaction between the effect of chronic
mucus hypersecretion and FEV1 percent predicted with
regard to total mortality which is in agreement with our
results. However, also in the same study, regarding
obstructive lung disease mortality, the effect of chronic
mucus hyper-secretion varied with the level of ventilatory
function, being weak in individuals with normal ventila-
tory function but more pronounced in individuals with
reduced ventilatory function. This interaction was statisti-
Table 3: Mortality risks among smokers within GOLD stages 1–4 in individuals with symptoms of chronic bronchitis, with individuals 
from the same GOLD stage without symptoms of chronic bronchitis as reference*
Gold stage Chr Br (%) Deaths HR** 95%CI p-value
Men
GOLD 1 44 (5.8) 25 2.04 1.34–3.11 0.001
GOLD 2 55 (8.3) 26 1.20 0.80–1.80 0.38
GOLD 3 17 (18.7) 9 0.71 0.34–1.51 0.38
GOLD 4 5 (20.8) 2 0.41 0.09–1.87 0.25
Women
GOLD 1 4 (2.4) 1 1.58 0.22–11.79 0.66
GOLD 2 17 (8.1) 7 3.16 1.38–7.23 0.006
GOLD 3 7 (21.2) 3 2.19 0.27–18.02 0.47
GOLD 4 3 (37.5) 2 0.58 0.08–4.11 0.59
* HR denotes hazard ratio, with CI: 95% confidence interval, Chr Br: symptoms of chronic bronchitis.
**Adjusted for age, tobacco consumption (>=20 g/<20 g tobacco) and inhalation habits.Page 6 of 9
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Copenhagen City Heart study population showed that
chronic mucus hyper-secretion was associated with later
hospitalization due to COPD, relative risks were 2.4 (1.3
to 4.5) for men and 2.6 (1.2 to 5.3) for women [16].
In contrast, in the National Health and Nutrition Exami-
nation Study (NHANES) the presence of respiratory
symptoms was not associated with an increased mortality
risk in subjects with normal lung function [14]. The rela-
tive risk (1.2) was elevated but not statistically significant
probably due to the fact that a much wider definition of
respiratory symptoms was used which included as well
individuals with wheeze and a diagnosis of asthma. In our
study based on a similar number of deaths, but also on a
more specific definition of respiratory symptoms (symp-
toms of chronic bronchitis) a HR of 1.6 was statistically
significant among smoking men.
Occupational studies have shown results in agreement
with our study. In a population of 1061 men working in
the Paris area and followed for 22 years, chronic phlegm
production was significantly associated with mortality:
Relative risk 1.35; (p less than 0.01) [6]. In a group of gold
miners, chronic mucus hyper-secretion was not related to
COPD mortality, but related to mortality in ischemic
heart disease and other causes after adjustment for
tobacco and dust exposure [17].
On the contrary, in another occupational cohort of 2,718
British men examined between 1954 and 1961, and fol-
lowed for 20 to 25 years, the risk of death from COPD was
correlated with the initial degree of air-flow obstruction.
Among men with similar initial air-flow obstruction, age-
specific COPD death rates were not significantly related to
initial mucus hypersecretion [18].
The explanation for the relation between chronic produc-
tive cough and future mortality risk is still unclear. Previ-
ously, in the classic study by Fletcher and coworkers,
conducted in a cohort of working men in London, chronic
phlegm production was unrelated to the development of
airway obstruction and regarded as a less important con-
dition [19]. Furthermore, the presence of stage 0 at base-
line was not a meaningful predictor for the subsequent
development of COPD in later stages after 5 and 15 years
follow-up in a Danish prospective population based study
[4].
Thus it seems that the symptoms of chronic bronchitis do
not affect the FEV1 decline and development of COPD to
the same extent that it affects all-cause and obstructive
lung disease mortality and risk of COPD hospitalization.
An explanation could be that symptoms of chronic bron-
chitis may be an independent pulmonary disorder associ-
ated with inflammatory and/or infectious exacerbations
[20] and possibly also with the development of other dis-
eases such as lung cancer [15] and thus not specifically
associated with COPD development and progression. We
were able to analyse cause specific mortality in GOLD
stage 0 in male smokers. Our findings of significantly
increased HR for lung cancer, all cancers, and other dis-
eases in individuals of stage 0 support this view.
Mortality risks in stages 1–4
GOLD stage 1 in our study, as well as in the NHANES
study [14], conveyed only a slight increase in total
mortality risk of borderline significance, even lower than
found for GOLD stage 0. Among former smokers there
was a tendency towards a decreased risk. Thus among
individuals who quit smoking when still in GOLD stage 1,
the future mortality risk will be normal. In GOLD stages 2
to 4 our findings of increased mortality HR are in agree-
ment with other previously conducted studies, as they
actually reflect a successive reduction in FEV1 [21-23].
Mortality risks were also increased among never smokers,
and these results are entirely in line with other studies
[24]. The NHANES study showed increased mortality risks
associated with moderate to severe COPD, among smok-
ers and former smokers of approximately the same mag-
nitude as we report [14].
Study limitations
A methodological limitation of these findings is the meas-
urement of pulmonary function. The protocol of the lung
function tests did not meet the standards of current rec-
ommendations [12]. The values of the internal regression
equation based on height and age and the standard devi-
ation of the equation is similar to that of the Working
party of the European Community for Steel and Coal [25].
Hence, we believe that the methodological error is similar
to the one achieved after optimal spirometric technique.
However there remains the possibility of misclassification
due to decreased specificity in the spirometries which
could have resulted in an underestimation of the results
rather than the reverse.
Another possible limitation of this study is dependent on
the fact that smoking prevalence in Sweden has decreased
since the 1970's [26]. Some smokers in this study are
likely to have stopped smoking during the follow-up time.
Smoking habits were assessed at one point in time and
not repeated thereafter. Hence, we have not been able to
calculate accumulated smoking exposure in terms of indi-
vidual pack-years. However, even the use of pack-years
has its limitations, especially with respect to recall biases
in subjects with a long history of smoking [27].
Furthermore, we have no follow-up data on symptoms of
chronic bronchitis and thus we were not able to deter-Page 7 of 9
(page number not for citation purposes)
Respiratory Research 2005, 6:98 http://respiratory-research.com/content/6/1/98mine whether the symptoms of chronic bronchitis were
stable or not. According to previous studies symptoms of
chronic bronchitis may disappear in some individuals [4].
In those individuals, symptoms of chronic bronchitis may
have a limited influence on mortality risks and could
cause an underestimation of the effect of persistent
symptoms of chronic bronchitis in this study. In addition,
we have no spirometric follow-up data and hence we are
not able to determine whether individuals with GOLD
stage 0 at baseline have developed COPD in the later
GOLD stages during the follow up time.
Another limitation of the study was the lower statistical
power in the analyses of women. Our findings in women,
especially in former smokers and never smokers should
therefore be interpreted with caution.
Implications of our findings
We believe that symptoms of chronic bronchitis should
be regarded as a marker for an increased all-cause mortal-
ity risk. Our data show that among middle-aged smokers,
symptoms of chronic bronchitis might represent an inde-
pendent risk factor for an early mortality equal to that of
having moderate COPD.
It is however uncertain from previous studies whether
symptoms of chronic bronchitis really are related to the
development and progression of COPD [4]. An increased
risk of COPD mortality associated with chronic mucus
hyper secretion among individuals with established
COPD has been shown previously [7]. In our study, symp-
toms of chronic bronchitis increased the risk of all cause
mortality and mortality in cancer, lung cancer and other
causes in smoking individuals with normal lung function
(stage 0) and the risk of total mortality in individuals with
GOLD stage 1 and 2. Our findings indicate that symptoms
of chronic bronchitis might be an independent pulmo-
nary disorder that may or may not be associated with
COPD. It is therefore questionable whether GOLD stage 0
should be used as an "at risk" stage for COPD develop-
ment in future COPD classifications.
Finally, GOLD stage 0 indicates a group of individuals
with a very unfavourable prognosis similar to that of indi-
viduals with GOLD stage 2. Among smokers, symptoms
of chronic bronchitis contributed to an adverse prognosis
not only in individuals "at risk", but also in those with
early stages of COPD with GOLD 1 and 2.
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